Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Karolinska Development AB ( (SE:KDEV) ) has shared an update.
At an Extraordinary General Meeting on 8 January 2026, Karolinska Development’s shareholders approved a rights issue of up to 675,193,985 new series B shares at SEK 0.30 each, open to existing shareholders on a preferential basis between 13 and 27 January 2026, potentially increasing the company’s share capital by up to SEK 6,751,939.85. The meeting also approved amendments to the Articles of Association, including changing the company’s name to KDventures AB and adjusting the permitted ranges for share capital and number of shares, steps that signal a strategic rebranding and capital strengthening aimed at supporting the firm’s investment activities and growth ambitions in the Nordic life sciences sector.
More about Karolinska Development AB
Karolinska Development AB (to be renamed KDventures AB) is a Nordic life sciences investment company listed on Nasdaq Stockholm that focuses on identifying and backing breakthrough medical innovations in the Nordic region. It builds and finances portfolio companies that develop innovative treatments for life‑threatening or seriously debilitating diseases, drawing on research from Karolinska Institutet and other leading universities and research institutes, and working alongside specialist international investors and experienced management teams.
Average Trading Volume: 808,922
Current Market Cap: SEK115.2M
For detailed information about KDEV stock, go to TipRanks’ Stock Analysis page.